4.7 Article

Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy

期刊

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 17, 期 10, 页码 E792-E798

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2013.07.002

关键词

MERS-CoV; Interferon; Ribavarin; SARS

资金

  1. University College London Hospitals NHS Foundation Trust
  2. National Institute of Health UCLH Biomedical Research Centre
  3. EDCTP
  4. EC-FW7

向作者/读者索取更多资源

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections. (C) 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据